{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:00:02Z","timestamp":1793916002134,"version":"4.8.0"},"reference-count":310,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Gastrointestinal (GI) cancers remain a leading cause of cancer-related morbidity and mortality worldwide despite major advances in systemic therapy. Although immune checkpoint inhibitors have improved outcomes in selected biomarker-defined populations, most GI malignancies, including microsatellite-stable colorectal cancer, pancreatic ductal adenocarcinoma, and many biliary tract tumors, remain largely resistant because of low tumor immunogenicity, stromal exclusion, immune suppression, and adaptive resistance mechanisms. Bispecific antibodies (BsAbs) have emerged as a rapidly expanding class of immunotherapeutics capable of simultaneously engaging two distinct targets, enabling mechanisms such as T-cell redirection, dual checkpoint inhibition, combined immune and anti-angiogenic modulation, tumor-selective co-stimulation, and stromal remodeling. Recent clinical advances, including the approval of HER2-targeted zanidatamab and the emergence of multiple late-phase studies across GI malignancies, have validated the therapeutic potential of this platform. This review examines the biological rationale, structural formats, and mechanisms of action of BsAbs and summarizes current clinical evidence across colorectal, gastric, gastroesophageal, hepatocellular, pancreatic, biliary tract, esophageal, and neuroendocrine cancers. We also discuss emerging therapeutic targets, biomarker-driven patient selection, safety considerations, combination strategies, manufacturing challenges, and future directions. Collectively, current evidence suggests that BsAbs are poised to become an increasingly important component of precision immunotherapy, with the potential to overcome key limitations of conventional immunotherapeutic approaches in GI oncology.<\/jats:p>","DOI":"10.3389\/fonc.2026.1927829","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:11:15Z","timestamp":1788955875000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives"],"prefix":"10.3389","volume":"16","author":[{"given":"Mariam","family":"Ismail","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Delta University for Science and Technology","place":["Gamasa, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noran","family":"Al-Gizey","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Baghdad","place":["Baghdad, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebtesam","family":"Al-Najjar","sequence":"additional","affiliation":[{"name":"Houston Methodist Cancer Center, Houston Methodist Hospital","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Alabed","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, the University of Jordan","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Mustafa","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, the University of Jordan","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Hamdaneh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, the University of Jordan","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Esmail","sequence":"additional","affiliation":[{"name":"Department of Medicine, Houston Methodist Cancer Center, Houston Methodist Hospital","place":["Houston, TX, United States"]},{"name":"Department of Medicine, Weill Cornell Medical College","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)01635-6","article-title":"The global, regional, and national burden of cancer, 1990\u20132023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"Force","year":"2025","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global burden of 5 major types of gastrointestinal cancer","volume":"159","author":"Arnold","year":"2020"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70245","article-title":"Gastrointestinal cancer statistics in 2022 and projection to 2050: GLOBOCAN estimates across 185 countries","volume":"132","author":"Danpanichkul","year":"2026"},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","article-title":"Recent developments in immunotherapy for gastrointestinal tract cancers","volume":"17","author":"Chong","year":"2024"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1641518","article-title":"Research progress on mechanisms of tumor immune microenvironment and gastrointestinal resistance to immunotherapy: mini review","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-3-030-41008-7_5","article-title":"Immunotherapy in gastrointestinal Malignancies","author":"Mizrahi","year":"2020"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000404","article-title":"Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal Malignancies","volume":"8","author":"Puccini","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71432","article-title":"The landscape of bispecific antibodies in solid tumor oncology: trends, challenges, and opportunities","volume":"14","author":"ElBeblawy","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2517729","article-title":"Zanidatamab with and without tislelizumab in HER2-positive gastroesophageal cancer","volume":"394","author":"Shitara","year":"2026"},{"key":"B12","doi-asserted-by":"publisher","first-page":"218417","DOI":"10.1016\/j.canlet.2026.218417","article-title":"Bispecific T-cell engager therapy for gastrointestinal cancers","author":"Burton","year":"2026","journal-title":"Clin Cancer Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2147\/dddt.s151282","article-title":"Bispecific antibodies: design, therapy, perspectives","author":"Sedykh","year":"2018","journal-title":"Drug Des Dev Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"108000","DOI":"10.1016\/j.phrs.2025.108000","article-title":"From molecular engineering to clinical applications: the expanding role of bispecific antibodies in onco-immunology","author":"Borrelli","year":"2025","journal-title":"Pharmacol Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.70011","article-title":"Bispecific antibodies, immune checkpoint inhibitors, and antibody- drug conjugates directing antitumor immune responses: challenges and prospects","volume":"42","author":"Li","year":"2024","journal-title":"Cell Biol Funct"},{"key":"B16","doi-asserted-by":"publisher","first-page":"218578","DOI":"10.1016\/j.canlet.2026.218578","article-title":"Bispecific antibodies for cancer therapy: evolution of structural formats and co-targeting strategies from wet-lab to AI-driven in silico modeling","author":"Fan","year":"2026","journal-title":"Clin Cancer Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of Malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4516041","article-title":"Immunoglobulin gamma\u2010like therapeutic bispecific antibody formats for tumor therapy","volume":"2019","author":"Chen","year":"2019","journal-title":"J Immunol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange","volume":"110","author":"Labrijn","year":"2013"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105268","article-title":"Trispecific antibodies: from challenges to integration in cancer therapy","volume":"222","author":"Bahr","year":"2026","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004122","article-title":"Colocalized targeting of TGF-\u03b2 and PD-L1 by bintrafusp alfa elicits distinct antitumor responses","volume":"10","author":"Lan","year":"2022"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5989","article-title":"Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy","volume":"11","author":"Claus","year":"2019","journal-title":"Sci Transl Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"14397","DOI":"10.1038\/s41598-021-93842-0","article-title":"Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning","volume":"11","author":"Haber","year":"2021","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-23-0233","article-title":"A bispecific antibody that targets the membrane-proximal region of mesothelin and retains high anticancer activity in the presence of shed mesothelin","volume":"23","author":"Chakraborty","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-25-0665","article-title":"JNJ-79032421, a novel membrane-restricted mesothelin-targeting T-cell-engaging bispecific antibody for the treatment of mesothelin-positive cancers","author":"Smans","year":"2026","journal-title":"Mol Cancer Ther"},{"key":"B29","article-title":"Nivolumab plus ipilimumab in microsatellite-instability\u2013high metastatic colorectal cancer","volume":"391","author":"Andre","year":"2024"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.05.008","article-title":"Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non\u2013small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial","volume":"116","author":"Reck","year":"2019"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae013","article-title":"The efficacy of immune checkpoint inhibitors in microsatellite stable colorectal cancer: a systematic review","volume":"29","author":"Guven","year":"2024"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00247-z","article-title":"Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer","volume":"2","author":"Westcott","year":"2021"},{"key":"B34","first-page":"217699","article-title":"Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited\u2013exploring the \u201cspace","volume":"622","author":"Br\u00e4utigam","year":"2025","journal-title":"Clin Immunol Lett"},{"key":"B35","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"B36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ajpath.2018.09.009","article-title":"The paradoxical web of pancreatic cancer tumor microenvironment","volume":"189","author":"Lafaro","year":"2019","journal-title":"Am J Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202201982rrr","article-title":"CXCL8 induces M2 macrophage polarization and inhibits CD8 (+) T cell infiltration to generate an immunosuppressive microenvironment in colorectal cancer","volume":"37","author":"Shao","year":"2023"},{"key":"B39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1706559114","article-title":"Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses","volume":"114","author":"Chew","year":"2017"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.4098","article-title":"Immune landscape of hepatocellular carcinoma: from dysregulation of the immune responses to the potential immunotherapies","volume":"42","author":"Pourbagheri\u2010Sigaroodi","year":"2024","journal-title":"Cell Biol Funct"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1158\/0008-5472.can-25-0079","article-title":"Tumor-associated macrophages produce PGE2 to promote CD8+ T-cell exhaustion and drive resistance to PD-L1 blockade in microsatellite-stable colorectal cancer","volume":"86","author":"Fumet","year":"2026"},{"key":"B44","article-title":"VEGF suppresses T\u2010lymphocyte infiltration in the tumor microenvironment through inhibition of NF\u2010\u03baB\u2010induced endothelial activation","volume":"29","author":"Huang","year":"2015"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3381","article-title":"The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review","volume":"7","author":"Pinter","year":"2021","journal-title":"J Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"108921","DOI":"10.1016\/j.biopha.2019.108921","article-title":"Intrinsic \u03b2-catenin signaling suppresses CD8+ T-cell infiltration in colorectal cancer","volume":"115","author":"Xue","year":"2019"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.01.013","article-title":"KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK\/ERK pathway in pancreatic cancer","volume":"446","author":"Cheng","year":"2019"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-0821","article-title":"KRAS inhibitors in pancreas cancer: facts and hopes about the immunotherapy we\u2019ve all been waiting for","author":"Stanger","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx271","article-title":"Tumor CDKN2A-associated JAK2 loss and susceptibility to immunotherapy resistance","volume":"110","author":"Horn","year":"2018"},{"key":"B52","doi-asserted-by":"publisher","first-page":"15440","DOI":"10.1038\/ncomms15440","article-title":"Acquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions","volume":"8","author":"Sucker","year":"2017"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016"},{"key":"B54","doi-asserted-by":"publisher","first-page":"105353","DOI":"10.1016\/j.critrevonc.2026.105353","article-title":"Overcoming conditional immune resistance in MSS and pMMR colorectal cancer: A sequential gating framework for immunotherapy","author":"Farah","year":"2026"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012330","article-title":"SPP1high macrophage-induced T-cell stress promotes colon cancer liver metastasis through SPP1\/CD44\/PI3K\/AKT signaling","volume":"13","author":"Ding","year":"2025"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2026.01.009","article-title":"Cytokine circuitry in pancreatic cancer: Targets for overcoming immune checkpoint inhibitor resistance in PDAC","author":"Suresh","year":"2026"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.6027","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1757513","DOI":"10.3389\/fimmu.2026.1757513","article-title":"Myeloid-derived suppressor cells and regulatory T cells in colorectal cancer: a synergistic immunosuppressive axis and emerging therapeutic opportunities","volume":"17","author":"Zhang","year":"2026"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.46094","article-title":"Liver metastases and immune checkpoint inhibitor efficacy in patients with refractory metastatic colorectal cancer: a secondary analysis of a randomized clinical trial","volume":"6","author":"Chen","year":"2023"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021"},{"key":"B61","doi-asserted-by":"publisher","first-page":"113433","DOI":"10.1016\/j.ejca.2023.113433","article-title":"Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting","volume":"196","author":"Saberzadeh-Ardestani","year":"2024"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-1696","article-title":"A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors","volume":"22","author":"Bacac","year":"2016"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-23-0766","article-title":"Optimizing the design and geometry of T cell\u2013engaging bispecific antibodies targeting CEA in colorectal cancer","volume":"23","author":"Elsayed","year":"2024"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-3275","article-title":"A novel GUCY2C-CD3 T-cell engaging bispecific construct (PF-07062119) for the treatment of gastrointestinal cancers","volume":"26","author":"Mathur","year":"2020"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1203498","article-title":"CEA TCB: a novel head-to-tail 2: 1 T cell bispecific antibody for treatment of CEA-positive solid tumors","volume":"5","author":"Bacac","year":"2016"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.3390\/cancers16234052","article-title":"Carcinoembryonic antigen expression in human tumors: a tissue microarray study on 13,725 tumors","volume":"16","author":"Jansen","year":"2024"},{"key":"B68","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/CJI.0b013e31819b7c70","article-title":"Potent control of tumor growth by CEA\/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA","volume":"32","author":"Lutterbuese","year":"2009","journal-title":"J Immunother"},{"key":"B69","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-026-04380-z","article-title":"Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial","author":"Melero","year":"2026"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.07.009","article-title":"Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen, in patients with advanced gastrointestinal adenocarcinomas","volume":"15","author":"Pishvaian","year":"2016"},{"key":"B72","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40425-019-0575-3","article-title":"CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids","volume":"7","author":"Gonzalez-Exposito","year":"2019"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024"},{"key":"B74","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/s1470-2045(23)00150-x","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023"},{"key":"B75","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40265-025-02253-2","article-title":"Targeting HER2 in metastatic colorectal cancer: Current therapies, biomarker refinement, and emerging strategies: C. Vaghi et\u00a0al","volume":"86","author":"Vaghi","year":"2026"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad200","article-title":"Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer: a systematic literature review and meta-analysis of clinical outcomes","volume":"28","author":"Bekaii-Saab","year":"2023"},{"key":"B77","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1158\/1538-7445.am2016-509","article-title":"HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer","volume":"7","author":"Takegawa","year":"2015"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(11)72627-2","article-title":"Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab","volume":"3","author":"Yonesaka","year":"2011"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/jso.25421","article-title":"Systemic treatment for metastatic colorectal cancer in the era of precision medicine","volume":"119","author":"Sandhu","year":"2019"},{"key":"B81","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Colon Cancer (Version 2.2026)","year":"2026"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022"},{"key":"B83","first-page":"4013","article-title":"Long-term outcomes and overall survival (OS) for zanidatamab+ chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA): 4-year follow-up of a phase 2 trial","volume-title":"2025 ASCO Annual Meeting","author":"Elimova","year":"2025"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-23-0838","article-title":"Co-clinical trial of novel bispecific anti-HER2 antibody zanidatamab in patient-derived xenografts","volume":"14","author":"DiPeri","year":"2024"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-2827","article-title":"First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: results from a phase I study","volume":"28","author":"Zhang","year":"2022"},{"key":"B86","first-page":"3621","article-title":"Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors","volume-title":"2023 ASCO Annual Meeting","author":"Gong","year":"2023"},{"key":"B87","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-025-02195-x","article-title":"Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4\/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study","volume":"10","author":"Liu","year":"2025"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2014.2663","article-title":"Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo","volume":"45","author":"Han","year":"2014"},{"key":"B89","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-25-0654","article-title":"TPP-45142\u2014an anti-HER2 T cell engager\u2014Designed for selective HER2-low cancer immunotherapy","author":"De Tavernier","year":"2026"},{"key":"B90","first-page":"1642454","article-title":"Trispecific eFab-eIg T-cell engagers targeting HER2 and HER3","volume":"16","author":"L\u00f6ffler","year":"2025"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-0823","article-title":"Mechanisms of innate and acquired resistance to anti-EGFR therapy: a review of current knowledge with a focus on rechallenge therapies","volume":"25","author":"Parseghian","year":"2019"},{"key":"B92","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/cancers15010183","article-title":"Molecular basis of HER2-targeted therapy for HER2-positive colorectal cancer","volume":"15","author":"Yoshikawa","year":"2022"},{"key":"B93","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13046-018-1019-5","article-title":"JAK\/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer","volume":"38","author":"Giordano","year":"2019"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1008764","DOI":"10.3389\/fimmu.2022.1008764","article-title":"LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager","volume":"13","author":"Corrales","year":"2022"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-21-0599","article-title":"Novel anti-LY6G6D\/CD3 T-cell\u2013dependent bispecific antibody for the treatment of colorectal cancer","volume":"21","author":"Wang","year":"2022"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2021.1937124","article-title":"Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential","volume":"25","author":"Entezari","year":"2021"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-011-8253-7","article-title":"GUCY2C-targeted cancer immunotherapy: past, present and future","volume":"51","author":"Snook","year":"2011"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.02.010","article-title":"An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers","volume":"31","author":"Zekri","year":"2023"},{"key":"B100","doi-asserted-by":"crossref","first-page":"2322562","DOI":"10.1080\/19420862.2024.2322562","article-title":"A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy","volume":"16","author":"Frey","year":"2024","journal-title":"mAbs"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013474","article-title":"Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM\/CD3-bispecific antibody engaging human T cells","volume":"5","author":"Herrmann","year":"2010"},{"key":"B102","doi-asserted-by":"publisher","first-page":"112424","DOI":"10.1016\/j.intimp.2024.112424","article-title":"IMT030122, a novel engineered EpCAM\/CD3\/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer","volume":"137","author":"Shen","year":"2024"},{"key":"B103","doi-asserted-by":"publisher","first-page":"JCO","DOI":"10.1200\/jco-25-02187","article-title":"Amivantamab monotherapy in chemorefractory RAS\/BRAF wild-type metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib\/II study","author":"Oberstein","year":"2026"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-0423","article-title":"Increased TGF-\u03b1 as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR\u2013MET interaction and activation of MET signaling in colon cancer cells","volume":"19","author":"Troiani","year":"2013"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1758251","DOI":"10.3389\/fonc.2026.1758251","article-title":"Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps","volume":"16","author":"Shao","year":"2026"},{"key":"B106","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS3678","article-title":"A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 T-cell engager in participants with advanced or metastatic microsatellite-stable (MSS)\/microsatellite instability\u2013low (MSI-L) colorectal cancer (CRC)","author":"Spira","year":"2026"},{"key":"B107","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS3636","article-title":"OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS\/BRAF wild-type metastatic colorectal cancer","author":"Arnold","year":"2025"},{"key":"B108","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1200\/jco.2026.44.16_suppl.3548","article-title":"Antitumor activity of amivantamab by consensus molecular subtypes in RAS\/BRAF wild-type metastatic colorectal cancer: Secondary analyses from the phase 1b\/2 OrigAMI-1 study","volume":"44","author":"Cruz-Correa","year":"2026"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2026-ct216","article-title":"OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS\/BRAF wild-type colorectal cancer","volume":"43","author":"Hecht","year":"2025"},{"key":"B110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.186","article-title":"Baseline biomarker analysis and clinical outcomes of the PD-1\/TGF\u03b2R2 bispecific antibody INCA33890 in patients with non-MSI-H metastatic colorectal cancer (mCRC)","author":"Moyers","year":"2026"},{"key":"B111","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.3576","article-title":"Ivonescimab (ivo) with oxaliplatin+ fluorouracil (5-FU)+ leucovorin calcium (mFOLFOX6) for patients (pts) with unresectable metastatic colorectal cancer (mCRC): A phase 2 study","author":"Berz","year":"2026"},{"key":"B112","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS3672","article-title":"Phase 2\/3 trial of pumitamig (PD-L1\u00d7 VEGF-A bsAb) plus chemotherapy versus bevacizumab plus chemotherapy in previously untreated, unresectable, or metastatic colorectal cancer (ROSETTA CRC-203)","author":"Biachi de Castria","year":"2026"},{"key":"B113","first-page":"TPS3675","article-title":"Symbiotic-GI-03: A randomized, double-blind, phase 3 study of first-line PF-08634404, a PD-1\/VEGF bispecific antibody, in combination with mFOLFOX6 in patients with metastatic colorectal cancer (mCRC)","volume-title":"2026 ASCO Annual Meeting","author":"Eng","year":"2026"},{"key":"B114","first-page":"TPS3682","article-title":"A randomized, active-controlled phase 3 study of ivonescimab+ FOLFOX versus bevacizumab+ FOLFOX as first-line treatment of metastatic colorectal cancer (mCRC): HARMONi-GI3","volume-title":"2026 ASCO Annual Meeting","author":"Parikh","year":"2026"},{"key":"B115","first-page":"3517","article-title":"Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients","author":"Saeed","year":"2025"},{"key":"B116","first-page":"TPS266","article-title":"A phase 1\/2, randomized, global trial to investigate efficacy and safety of EpCAM\u00d7 4-1BB bsAb (BNT314\/GEN1059) in combination with pumitamig (BNT327; PD-L1\u00d7 VEGF-A bsAb) and chemotherapy in patients with metastatic colorectal cancer (mCRC)","volume-title":"2026 ASCO Gastrointestinal Cancers Symposium","author":"Elez","year":"2026"},{"key":"B117","article-title":"Gastric cancer: A review","volume":"335","author":"Patel","year":"2026"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02331","article-title":"Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline","volume":"41","author":"Shah","year":"2023"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar","year":"2025"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-3726","article-title":"FDA approval summary: Pembrolizumab for the treatment of HER2-positive gastric cancer","volume":"32","author":"Casak","year":"2026","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004080","article-title":"Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer","volume":"10","author":"Bai","year":"2022"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3390\/cancers18091448","article-title":"Bispecific antibodies and antibody\u2013drug conjugates in advanced gastric adenocarcinoma","volume":"18","author":"Rogers","year":"2026"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04597-8","article-title":"Safety and preliminary efficacy results of IBI389, an anti-Claudin18. 2\u00d7 CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study","author":"Li","year":"2026"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024"},{"key":"B128","first-page":"102418","article-title":"Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review","volume":"108","author":"Blang\u00e9","year":"2022"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-19-0455","article-title":"HER-family ligands promote acquired resistance to trastuzumab in gastric cancer","volume":"18","author":"Sampera","year":"2019"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-334667","article-title":"Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy","volume":"75","author":"Sheng","year":"2026"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"Weisser","year":"2023"},{"key":"B132","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1038\/s41467-025-59279-z","article-title":"Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial","volume":"16","author":"Meric-Bernstam","year":"2025"},{"key":"B133","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.LBA285","article-title":"Zanidatamab+ chemotherapy (CT)\u00b1tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): Primary analysis from HERIZON-GEA-01","author":"Elimova","year":"2026"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2022.10.004","article-title":"KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer","volume":"178","author":"Xu","year":"2023"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1267891","article-title":"Overcoming resistance to HER2-targeted therapy with a novel HER2\/CD3 bispecific antibody","volume":"6","author":"Lopez-Albaitero","year":"2017"},{"key":"B136","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s13046-019-1354-1","article-title":"A novel asymmetrical anti-HER2\/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells","volume":"38","author":"Yu","year":"2019"},{"key":"B137","doi-asserted-by":"publisher","first-page":"2303908","DOI":"10.1002\/advs.202303908","article-title":"Anti\u2010PD\u20101\/Her2 bispecific antibody IBI315 enhances the treatment effect of Her2\u2010positive gastric cancer through gasdermin B\u2010cleavage induced pyroptosis","volume":"10","author":"Lin","year":"2023"},{"key":"B138","doi-asserted-by":"publisher","first-page":"103141","DOI":"10.1016\/j.ctrv.2026.103141","article-title":"Targeting claudins in gastric cancer: A novel GLOWing strategy in the SPOTLIGHT","author":"Balsa","year":"2026"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000002464","article-title":"Claudin 18.2 and other therapeutic biomarkers in gastric and gastroesophageal junction adenocarcinomas","volume":"49","author":"Liu","year":"2025"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-026-01803-9","article-title":"Claudin18. 2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies","author":"Xie","year":"2026"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18. 2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2026.2615855","article-title":"Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18. 2-positive gastroesophageal adenocarcinoma","author":"Egebjerg","year":"2026"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.06.037","article-title":"CLDN18. 2 BiTE engages effector and regulatory T cells for antitumor immune response in preclinical models of pancreatic cancer","volume":"165","author":"Xu","year":"2023"},{"key":"B145","doi-asserted-by":"publisher","first-page":"8420","DOI":"10.1038\/s41598-019-44874-0","article-title":"Targeting CLDN18. 2 by CD3 bispecific and ADC modalities for the treatments of gastric and pancreatic cancer","volume":"9","author":"Zhu","year":"2019"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011857","article-title":"An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release","volume":"13","author":"Gaspar","year":"2025"},{"key":"B147","first-page":"4003","article-title":"First-line treatment of QLS31905 plus chemotherapy in patients with pancreatic cancer and gastric cancer: Data from a phase 1b\/2 study","volume-title":"2026 ASCO Annual Meeting","author":"Zhang","year":"2026"},{"key":"B148","first-page":"4036","article-title":"Phase I\/II trial of anti-CLDN18. 2\/PD-L1 recombinant humanized bispecific antibody Q-1802 plus XELOX in treatment-naive CLDN18. 2-positive advanced GC\/GEJ","volume-title":"2026 ASCO Annual Meeting","author":"Gong","year":"2026"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.30750501","article-title":"A first-in-human study of givastomig, a CLDN18. 2 and 4-1BB bispecific antibody, as monotherapy in patients with CLDN18. 2-positive advanced or metastatic solid tumors","volume":"31","author":"Ku","year":"2025"},{"key":"B150","first-page":"2662","article-title":"First-in-human phase I\/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18. 2 and 4-1BB, in patients with advanced solid tumors","volume-title":"2024 ASCO Annual Meeting","author":"Guo","year":"2024"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-026-02972-w","article-title":"Intratumoral heterogeneity and chemotherapy-induced alteration of CLDN18. 2 expression in resectable gastric cancer","author":"Nagano","year":"2026"},{"key":"B152","doi-asserted-by":"publisher","first-page":"28958","DOI":"10.1038\/s41598-025-12337-4","article-title":"The expression of the tight junction protein and therapeutical target claudin 18.2 is heterogeneously distributed within esophageal and gastric adenocarcinoma","volume":"15","author":"Pak","year":"2025"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.3389\/fonc.2019.01466","article-title":"Overexpression of B7-H3 in \u03b1-SMA-positive fibroblasts is associated with cancer progression and survival in gastric adenocarcinomas","volume":"9","author":"Zhan","year":"2020"},{"key":"B154","doi-asserted-by":"publisher","first-page":"108153","DOI":"10.1016\/j.intimp.2021.108153","article-title":"The role of B7-H3 in tumors and its potential in clinical application","volume":"101","author":"Feng","year":"2021"},{"key":"B155","doi-asserted-by":"publisher","first-page":"188783","DOI":"10.1016\/j.bbcan.2022.188783","article-title":"To kill a cancer: targeting the immune inhibitory checkpoint molecule, B7-H3","volume":"1877","author":"Kanchan","year":"2022"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1163136","DOI":"10.3389\/fimmu.2023.1163136","article-title":"IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer","volume":"14","author":"Lutz","year":"2023"},{"key":"B157","first-page":"e14509","article-title":"A novel B7-H3 x CD3 bispecific T-cell engager for the treatment of B7-H3+ tumors","volume-title":"2024 ASCO Annual Meeting","author":"Li","year":"2024"},{"key":"B158","doi-asserted-by":"publisher","first-page":"115032","DOI":"10.1016\/j.intimp.2025.115032","article-title":"A fc-engineered NKG2D\u00d7 B7-H3 bispecific antibody enhances the antitumor activity by orchestrating cytotoxic lymphocytes","volume":"161","author":"Yang","year":"2025"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70653","article-title":"Safety, pharmacokinetics, and pharmacodynamics evaluation of ivonescimab, a novel bispecific antibody targeting PD\u20101 and VEGF, in Chinese patients with advanced solid tumors","volume":"14","author":"Wang","year":"2025"},{"key":"B160","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018"},{"key":"B161","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS4239","article-title":"Phase II study evaluating ivonescimab in combination with chemotherapy as first-and second-line treatment of advanced or metastatic gastric and gastroesophageal adenocarcinoma patients (UCGI 52\u2013GRACIE)","volume-title":"2026 ASCO Annual Meeting","author":"De La Fouchardiere","year":"2026"},{"key":"B162","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS4246","article-title":"A single-arm, phase II study of ivonescimab in combination with FOLFOX in advanced HER2-negative gastroesophageal adenocarcinomas","author":"Durbin","year":"2026"},{"key":"B163","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.4048","article-title":"Cadonilimab in combination with ivonescimab and chemotherapy as first-line (1L) therapy in patients with advanced gastric (G) or gastroesophageal junction adenocarcinoma (GEJA): Updated results from an open-label phase II trial","author":"Wang","year":"2026"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03450-4","article-title":"First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial","volume":"31","author":"Shen","year":"2025","journal-title":"Nat Med"},{"key":"B165","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.e16040","article-title":"First-line (1L) cadonilimab plus AK117 and chemotherapy (chemo) in advanced gastric or gastroesophageal junction cancer (GC\/GEJC): Updated results from a phase 2 study","author":"Xia","year":"2026"},{"key":"B166","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.4100","article-title":"Neoadjuvant cadonilimab plus chemotherapy for locally advanced gastric\/gastroesophageal junction cancer: a single-arm, phase II trial","author":"Zhang","year":"2026"},{"key":"B167","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4182","article-title":"GEMINI-Gastric: a phase 2 study of novel treatment combinations in patients with locally advanced unresectable or metastatic gastric cancers","author":"Shen","year":"2024"},{"key":"B168","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/1078-0432.ccr-25-3447","article-title":"Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1\/CTLA-4 bispecific antibody","author":"Tran","year":"2026"},{"key":"B169","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s10555-025-10269-z","article-title":"Novel immunotherapy for gastric cancer: targeting the CD47\u2013SIRP\u03b1 axis","volume":"44","author":"Ooki","year":"2025"},{"key":"B170","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00262-024-03667-9","article-title":"Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer","volume":"73","author":"Zhang","year":"2024"},{"key":"B171","first-page":"2655","article-title":"The differentiated SIRP\u03b1\u2013IgG4 Fc fusion protein HCB101 in monotherapy and combination therapy","volume-title":"2026 ASCO Annual Meeting","author":"Ning","year":"2026"},{"key":"B172","first-page":"372","article-title":"Dose-dependent antitumor activity of HCB101 plus ramucirumab and paclitaxel in previously treated gastric cancer","volume-title":"2026 ASCO Gastrointestinal Cancers Symposium","author":"Yu","year":"2026"},{"key":"B173","first-page":"TPS460","article-title":"ARTEMIDE-Gastric01: a phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC\/GEJC)","author":"Shah","year":"2026"},{"key":"B174","first-page":"102991","article-title":"T-cell engager toxicity in clinical phase trials; a systematic review and meta-analysis","volume":"139","author":"Za\u00efr","year":"2025"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-3667","article-title":"Dissecting the mechanisms underlying the cytokine release syndrome (CRS) mediated by T-cell bispecific antibodies","volume":"29","author":"Leclercq-Cohen","year":"2023"},{"key":"B176","first-page":"114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"G\u00e9raud","year":"2024"},{"key":"B177","first-page":"123","article-title":"First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors","author":"Desai","year":"2025"},{"key":"B178","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.e23336","article-title":"Early toxicity and temporal mortality patterns following bispecific T-cell engager therapy: a real-world multicenter analysis","author":"Dastagir","year":"2026"},{"key":"B179","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/cancers17020291","article-title":"In vitro evaluation of the safety and efficacy of cibisatamab using adult stem cell-derived organoids and colorectal cancer spheroids","volume":"17","author":"Anstett","year":"2025"},{"key":"B180","doi-asserted-by":"publisher","first-page":"9651","DOI":"10.1038\/s41467-025-65148-6","article-title":"Modeling and addressing on-target\/off-tumor toxicity of claudin 18.2 targeted immunotherapies","volume":"16","author":"Carstens","year":"2025"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-01090","article-title":"Guanylyl cyclase 2C\u2013targeted chimeric antigen receptor T-cell therapy in patients with metastatic colorectal cancer","author":"Qi","year":"2026"},{"key":"B182","doi-asserted-by":"publisher","first-page":"1693179","DOI":"10.3389\/fimmu.2026.1693179","article-title":"Efficacy and safety of cadonilimab combined with chemotherapy for gastric or gastroesophageal junction adenocarcinoma: a single-arm meta-analysis","volume":"17","author":"Yang","year":"2026"},{"key":"B183","doi-asserted-by":"publisher","first-page":"28059","DOI":"10.18632\/oncotarget.8574","article-title":"Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fc\u03b3 receptors","volume":"7","author":"Borlak","year":"2016"},{"key":"B184","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/jco.2026.44.16_suppl.3016","article-title":"A phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: first disclosure of clinical data","volume":"44","author":"Chon","year":"2026"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71210","article-title":"The safety of cadonilimab: a systematic review and single\u2010arm meta\u2010analysis","volume":"14","author":"Zhang","year":"2025"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.5048","article-title":"Catumaxomab for the treatment of Malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study","volume":"24","author":"Berek","year":"2014"},{"key":"B187","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2584374","article-title":"Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2+1 TCBs","volume-title":"mAbs","author":"Abdelmotaleb","year":"2025"},{"key":"B188","doi-asserted-by":"publisher","first-page":"715719","DOI":"10.3389\/fimmu.2021.715719","article-title":"Protease-activation of fc-masked therapeutic antibodies to alleviate off-tumor cytotoxicity","volume":"12","author":"Elter","year":"2021"},{"key":"B189","doi-asserted-by":"publisher","first-page":"1679092","DOI":"10.3389\/fimmu.2025.1679092","article-title":"Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives","volume":"16","author":"Lopatnikova","year":"2025"},{"key":"B190","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2373325","article-title":"Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy","volume-title":"mAbs","author":"McCue","year":"2024"},{"key":"B191","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/s0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","author":"Rimassa","year":"2025"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025"},{"key":"B197","unstructured":"National Comprehensive Cancer Network. Hepatocellular Carcinoma (Version 1.2026)\n          \n          2026"},{"key":"B198","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","article-title":"Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review","volume":"10","author":"Cappuyns","year":"2024"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1111\/febs.12126","article-title":"Glypican\u20103: a marker and a therapeutic target in hepatocellular carcinoma","volume":"280","author":"Filmus","year":"2013"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2024.114391","article-title":"GPC-3 in hepatocellular carcinoma; a novel biomarker and molecular target","volume":"444","author":"Tehrani","year":"2025","journal-title":"Exp Cell Res"},{"key":"B202","doi-asserted-by":"publisher","first-page":"107671","DOI":"10.4254\/wjh.v17.i9.107671","article-title":"Targeting glypican-3 as a new frontier in liver cancer therapy","volume":"17","author":"Wu","year":"2025"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.004","article-title":"Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma","volume":"65","author":"Abou-Alfa","year":"2016"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-20-1025","article-title":"Combination therapy of hepatocellular carcinoma by GPC3-targeted bispecific antibody and irinotecan is potent in suppressing tumor growth in mice","volume":"21","author":"Chen","year":"2022"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000349","article-title":"Development of a tetravalent T-cell engaging bispecific antibody against glypican-3 for hepatocellular carcinoma","volume":"44","author":"Yu","year":"2021"},{"key":"B206","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/15384047.2020.1743158","article-title":"A novel targeted GPC3\/CD3 bispecific antibody for the treatment hepatocellular carcinoma","volume":"21","author":"Yu","year":"2020"},{"key":"B207","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s10637-025-01530-x","article-title":"Novel GPC3 N-terminal bispecific antibody exhibits dual anti-tumor effect against tumor cells","volume":"43","author":"Zhou","year":"2025"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-24-1049","article-title":"Identification and nonclinical characterization of SAR444200, a novel anti-GPC3 NANOBODY T-cell engager, for the treatment of GPC3+ solid tumors","author":"Meoni","year":"2025"},{"key":"B209","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.2521","article-title":"Phase 1\/2, open-label, first-in-human study of the anti-GPC3 T-cell engager SAR444200 in patients with advanced solid tumors: updated efficacy and biomarker analysis","volume-title":"J Clin Oncol","author":"Dumbrava","year":"2025"},{"key":"B210","first-page":"TPS4215","article-title":"RHEA-1: First-in-human (FIH) study of AZD9793, a first-in-class CD8-guided T cell-engager (TCE) for glypican-3-positive (GPC3+) advanced or metastatic hepatocellular carcinoma (HCC)","author":"Champiat","year":"2025"},{"key":"B211","doi-asserted-by":"publisher","first-page":"11111","DOI":"10.1038\/s41467-025-66087-y","article-title":"Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma","volume":"16","author":"Huang","year":"2025"},{"key":"B212","first-page":"1247","article-title":"Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC","volume":"71","author":"Shigeta","year":"2019"},{"key":"B213","doi-asserted-by":"publisher","first-page":"151878","DOI":"10.1016\/j.ijbiomac.2026.151878","article-title":"A rationally designed bispecific antibody targeting GPC3 and PD-L1 induces tumor-directed immune activation and cytotoxicity","author":"Yuan","year":"2026"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.01.006","article-title":"A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC","volume":"29","author":"Du","year":"2021"},{"key":"B215","doi-asserted-by":"publisher","first-page":"1599764","DOI":"10.3389\/fimmu.2025.1599764","article-title":"Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody","volume":"16","author":"Chen","year":"2025"},{"key":"B216","first-page":"4014","article-title":"Nilvanstomig (ZG005), an anti-PD-1\/TIGIT bispecific antibody, plus bevacizumab vs. sintilimab plus bevacizumab biosimilar as first-line therapy for advanced hepatocellular carcinoma: A randomized, multi-center, phase II trial","author":"Wu","year":"2026"},{"key":"B217","first-page":"e16212","article-title":"Ivonescimab (PD-1\/VEGF bispecific antibody) combined with HAIC for first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II study","author":"Li","year":"2025"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30795-8","article-title":"Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future","volume":"21","author":"Christenson","year":"2020"},{"key":"B219","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (Version 2.2026)\n          \n          2026"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3452","article-title":"Facts and hopes in immunotherapy of pancreatic cancer","volume":"28","author":"Bockorny","year":"2022"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(23)00207-8","article-title":"The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy","volume":"8","author":"Hilmi","year":"2023"},{"key":"B222","unstructured":"FDA Grants Accelerated Approval to Zenocutuzumab-Zbco for non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma\n          \n          2024"},{"key":"B223","doi-asserted-by":"publisher","first-page":"115671","DOI":"10.1016\/j.addr.2025.115671","article-title":"Classic versus innovative strategies for immuno-therapy in pancreatic cancer","author":"Formelli","year":"2025"},{"key":"B224","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3390\/biom15101477","article-title":"Bispecific antibody and antibody-drug conjugate as novel candidates for treating pancreatic ductal adenocarcinoma","volume":"15","author":"Seo","year":"2025"},{"key":"B225","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani","year":"2001"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: ready for prime time","volume":"34","author":"Hassan","year":"2016"},{"key":"B227","doi-asserted-by":"publisher","first-page":"422","DOI":"10.7150\/ijms.39012","article-title":"Overexpression of mesothelin in pancreatic ductal adenocarcinoma (PDAC)","volume":"17","author":"Le","year":"2020"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2021.1943747","article-title":"Mesothelin is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness","volume":"39","author":"Weidemann","year":"2021"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01367-8","article-title":"Targeting mesothelin in solid tumours: anti-mesothelin antibody and drug conjugates","volume":"25","author":"Chu","year":"2023"},{"key":"B230","doi-asserted-by":"publisher","first-page":"1651687","DOI":"10.3389\/fimmu.2025.1651687","article-title":"High mesothelin expression is associated with low cytotoxic T cell infiltration in pancreatic cancer","volume":"16","author":"Liang","year":"2025"},{"key":"B231","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1739408","article-title":"Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors","volume-title":"mAbs","author":"Hatterer","year":"2020"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-3392","article-title":"Preclinical characterization of HPN536, a trispecific, T-cell\u2013activating protein construct for the treatment of mesothelin-expressing solid tumors","volume":"27","author":"Molloy","year":"2021"},{"key":"B233","doi-asserted-by":"publisher","first-page":"2250309","DOI":"10.1002\/eji.202250309","article-title":"NAV\u2010003, a bispecific antibody targeting a unique mesothelin epitope and CD3\u03f5 with improved cytotoxicity against humoral immunosuppressed tumors","volume":"53","author":"Grasso","year":"2023"},{"key":"B234","doi-asserted-by":"publisher","first-page":"2233401","DOI":"10.1080\/2162402x.2023.2233401","article-title":"An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin","volume":"12","author":"Snell","year":"2023"},{"key":"B235","first-page":"TPS3160","article-title":"Design of a first-in-human multicenter open-label study of ZW171, a mesothelin x CD3 targeting bispecific T-cell engager, in participants with advanced solid tumors: ZWI-ZW171-101","author":"Johnson","year":""},{"key":"B236","doi-asserted-by":"publisher","first-page":"1524899","DOI":"10.3389\/fimmu.2025.1524899","article-title":"Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer","volume":"16","author":"Zhu","year":"2025"},{"key":"B237","doi-asserted-by":"publisher","first-page":"1809374","DOI":"10.3389\/fmed.2026.1809374","article-title":"Expression of Claudin-18.2 in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis","volume":"13","author":"Al Subhi","year":"2026"},{"key":"B238","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1538-7445.am2025-5915","article-title":"Real world clinical characteristics of claudin 18.2 expression in patients with pancreatic adenocarcinoma","author":"Kerper","year":"2026"},{"key":"B239","first-page":"4188","article-title":"Prevalence and prognostic value of Claudin 18.2 expression in pancreatic ductal adenocarcinoma","author":"Lim","year":"2026"},{"key":"B240","doi-asserted-by":"publisher","first-page":"106014","DOI":"10.1016\/j.humpath.2025.106014","article-title":"High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation for targeted therapy","author":"Franzina","year":"2025"},{"key":"B241","first-page":"4035","article-title":"Real-world adoption and sequencing of CLDN18. 2, PD-L1, and HER2 testing in advanced gastric and gastroesophageal junction adenocarcinoma","author":"Zhang","year":"2026"},{"key":"B242","first-page":"709","article-title":"Phase 1\/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)","author":"Saeed","year":"2026"},{"key":"B243","first-page":"4192","article-title":"Spevatamig (PT886), a claudin 18.2 (CLDN18. 2)\/CD47 bispecific antibody, in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)","author":"Saeed","year":"2026"},{"key":"B244","doi-asserted-by":"publisher","first-page":"1168444","DOI":"10.3389\/fimmu.2023.1168444","article-title":"Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer","volume":"14","author":"Rabia","year":"2023"},{"key":"B245","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-024-01538-5","article-title":"Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma","volume":"17","author":"Long","year":"2024"},{"key":"B246","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1186\/s12885-022-10165-7","article-title":"Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4","volume":"22","author":"Hao","year":"2022"},{"key":"B247","doi-asserted-by":"publisher","first-page":"115653","DOI":"10.1016\/j.intimp.2025.115653","article-title":"Enhancing anti-tumor immunity through TIGIT blockade and tumor-directed targeting in pancreatic cancer","volume":"167","author":"Um","year":"2025"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-4001","article-title":"Fibroblast activation protein \u03b1-targeted CD40 agonism abrogates systemic toxicity and enables administration of high doses to induce effective antitumor immunity","volume":"27","author":"Sum","year":"2021"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-014620","article-title":"FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters","volume":"14","author":"Nguyen","year":"2026"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12982","article-title":"Cancer\u2010associated fibroblasts: key players in shaping the tumor immune microenvironment","volume":"302","author":"Desbois","year":"2021"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23179","article-title":"Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy","volume":"59","author":"Torphy","year":"2020"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021"},{"key":"B253","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1200\/jco.2026.44.16_suppl.4160","article-title":"Durvalumab or pembrolizumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy for advanced cholangiocarcinoma: a meta-analysis","volume":"44","author":"Esmail","year":"2026"},{"key":"B254","doi-asserted-by":"publisher","first-page":"75.0","DOI":"10.1200\/jco.2023.41.4_suppl.540","article-title":"CTX-009 (ABL001), a bispecific antibody targeting DLL4 and VEGF A, in combination with paclitaxel in patients with advanced biliary tract cancer (BTC): a phase 2 study","volume":"18","author":"Oh","year":"2023"},{"key":"B255","unstructured":"NCCN clinical practice guidelines in oncology version 1.2026 biliart tract cancers 2026\n          \n          \n          \n          2026"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.09.004","article-title":"Rational development of combination therapies for biliary tract cancers","volume":"78","author":"Harding","year":"2023"},{"key":"B257","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.3390\/cancers15133312","article-title":"Immunotherapy in biliary tract cancers: current standard-of-care and emerging strategies","volume":"15","author":"Lo","year":"2023"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30733-8","article-title":"Second-line therapies in advanced biliary tract cancers","volume":"21","author":"Tella","year":"2020"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2025.2556903","article-title":"An evaluation of zanidatamab, a novel, anti-HER2 biparatopic antibody, for the treatment of biliary tract cancer","volume":"25","author":"Yoon","year":"2025"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.4736","article-title":"Zanidatamab in HER2-positive metastatic biliary tract cancer: final results from HERIZON-BTC-01","volume":"12","author":"Pant","year":"2026"},{"key":"B261","first-page":"545","article-title":"Landmark analysis of overall survival (OS) by objective response in patients (pts) with previously treated, advanced HER2-positive biliary tract cancer (BTC): Post hoc analysis of the HERIZON-BTC-01 trial","author":"Harding","year":"2026"},{"key":"B262","doi-asserted-by":"publisher","first-page":"115432","DOI":"10.1016\/j.ejca.2025.115432","article-title":"Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers","volume":"222","author":"Smolenschi","year":"2025"},{"key":"B263","first-page":"4101","article-title":"Survival outcomes for zanidatamab-hrii compared to chemotherapy in previously treated HER2-positive (IHC3+) biliary tract cancer (BTC): HERIZON-BTC-01 vs a real-world (RW) external control arm (ECA)","author":"Kim","year":"2025"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000564","article-title":"Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with pretreated biliary tract cancer","volume":"8","author":"Yoo","year":"2020"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000965","article-title":"Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: a randomized phase 2\/3 trial","volume":"81","author":"Oh","year":"2025","journal-title":"Hepatol (Baltimore Md)"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23373","article-title":"Setting up clinical trials for success: applying preclinical advances in combined TGF\u03b2\/PD\u2010L1 inhibition to ongoing clinical studies","volume":"61","author":"Strait","year":"2022"},{"key":"B268","first-page":"e16077","article-title":"Efficacy of bintrafusp alfa (M7824) in patients with gastrointestinal tumors: a meta-analysis","author":"Barakat","year":"2025"},{"key":"B269","first-page":"TPS4184","article-title":"Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers","author":"Chapin","year":"2023"},{"key":"B270","first-page":"e16239","article-title":"Cadonilimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (BicureX): a phase II, single-arm clinical trial","author":"Ma","year":"2025"},{"key":"B271","first-page":"e16177","article-title":"A phase II, exploratory trial of cadonilimab (AK104) plus gemcitabine-cisplatin (GC) as a conversion therapy for patients (pts) with unresectable or systemic treatment\u2013failed biliary tract cancer (BTC)","author":"Liu","year":"2026"},{"key":"B272","first-page":"e16178","article-title":"Later-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced biliary tract cancer: a prospective, phase 2 trial","author":"Li","year":"2026"},{"key":"B273","first-page":"4095","article-title":"The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer","author":"Ying","year":"2024"},{"key":"B274","first-page":"e16170","article-title":"Ivonescimab plus gemcitabine\/cisplatin and stereotactic body radiotherapy as first-line treatment for advanced biliary tract cancer: a single-arm, open-label, phase II exploratory study","author":"Tao","year":"2026"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2351351","article-title":"COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC","volume":"20","author":"Azad","year":"2024"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00171-0","article-title":"Current and emerging therapies for advanced biliary tract cancers","volume":"6","author":"Kam","year":"2021"},{"key":"B277","first-page":"TPS587","article-title":"A phase 2\/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002","author":"Aranha","year":"2024"},{"key":"B278","doi-asserted-by":"publisher","first-page":"105049","DOI":"10.1016\/j.esmoop.2025.105049","article-title":"Claudin 18.2: a promising actionable target in biliary tract cancers","volume":"10","author":"Angerilli","year":"2025"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1111\/his.15407","article-title":"Expression of claudin\u201018.2 in cholangiocarcinoma: a comprehensive immunohistochemical analysis from a German tertiary centre","volume":"86","author":"Kinzler","year":"2025"},{"key":"B280","article-title":"Landscape analysis of CLDN18 expression and isoform distribution in solid tumors: insights from MONSTAR-SCREEN-2 study","volume":"116","author":"Hashimoto","year":"2025"},{"key":"B281","first-page":"e16152","article-title":"Two stage, multi-center trial of cadonilimab and LM-302 for patients with CLDN18. 2+ biliary tract cancer (BTC) that failed chemotherapy and PD-(L) 1 antibody (ZSAB-Calm)","author":"Fan","year":"2024"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1172\/jci182417","article-title":"Identification of potent biparatopic antibodies targeting FGFR2 fusion\u2013driven cholangiocarcinoma","volume":"135","author":"Chaturantabut","year":"2025"},{"key":"B283","doi-asserted-by":"publisher","first-page":"155175","DOI":"10.1016\/j.prp.2024.155175","article-title":"Cadherin-17 (CDH17) expression in human cancer: a tissue microarray study on 18,131 tumors","volume":"256","author":"Jacobsen","year":"2024"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-026-03693-8","article-title":"Cadherin 17 and digestive cancers: from diagnostic to therapeutic opportunities","author":"Fernandez","year":"2026"},{"key":"B285","first-page":"3603","article-title":"Phase 1, FIH study of cabotamig, a TCE CDH17 X CD3, in CDH17-expressing GI Malignancies","author":"Leung","year":"2026"},{"key":"B286","first-page":"96","article-title":"Selective tumor cell apoptosis and tumor regression in CDH17-positive colorectal cancer models using BI 905711, a novel liver-sparing TRAILR2 agonist","volume":"20","author":"Garc\u00eda-Mart\u00ednez","year":"2021"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000365","article-title":"Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced\/metastatic biliary tract cancers","volume":"78","author":"Yoo","year":"2023"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31462-9","article-title":"Oesophageal cancer (Primer)","author":"Smyth","year":"2017"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021"},{"key":"B290","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023"},{"key":"B293","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2026.44.16_suppl.e16083","article-title":"Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line treatment for unresectable or metastatic esophageal carcinoma: a systematic review and meta-analysis of randomized trials","volume":"44","author":"Kotte","year":"2026"},{"key":"B294","unstructured":"NCCN guidelines version 3.2026 esophageal and esophagogastric junction cancers 2026\n          \n          \n          \n          2026"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00401-2","article-title":"Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"27","author":"Hsu","year":"2026"},{"key":"B296","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/s1470-2045(25)00402-4","article-title":"First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b\/2 trial","volume":"27","author":"Sun","year":"2026"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012869","article-title":"Cadonilimab combined with taxane and cisplatin as the first-line treatment of advanced esophageal squamous cell carcinoma: an open-label, multicenter phase II trial","volume":"13","author":"Qu","year":"2025"},{"key":"B298","first-page":"TPS506","article-title":"Neoadjuvant cadonilimab plus anlotinib followed by surgery for locally advanced esophageal squamous cell carcinoma: a single arm, phase 2 trial","author":"Weng","year":"2025"},{"key":"B299","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s00262-024-03769-4","article-title":"First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial","volume":"73","author":"Zhao","year":"2024"},{"key":"B300","first-page":"410","article-title":"Neoadjuvant SHR-1701 (a bifunctional anti-PD-L1\/TGF-\u03b2RII agent) combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): a phase II trial","author":"Liu","year":"2025"},{"key":"B301","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-69703-7","article-title":"B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities","author":"Guan","year":"2026"},{"key":"B302","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac161","article-title":"DLL3 as an emerging target for the treatment of neuroendocrine neoplasms","volume":"27","author":"Yao","year":"2022"},{"key":"B303","first-page":"3004","article-title":"Efficacy and safety of the DLL3\/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial","author":"Capdevila","year":"2025"},{"key":"B304","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2026-ct222","article-title":"Obrixtamig (BI 764532) in patients with relapsed\/refractory delta-like ligand 3 (DLL3) high-expressing extrapulmonary neuroendocrine carcinoma (epNEC): trial in progress of the dose expansion part of the Phase II DAREON-5 trial","volume":"86","author":"Pavel","year":"2026"},{"key":"B305","first-page":"4004","article-title":"A randomized phase II dose optimization study for alveltamig (ZG006), a trispecific T-cell engager targeting DLL3\/DLL3\/CD3, as monotherapy in patients with refractory neuroendocrine carcinoma (ZG006-003)","author":"Zhao","year":"2026"},{"key":"B306","first-page":"TPS8128","article-title":"An open-label, multicenter, phase 1\/2 study of peluntamig (PT217), an anti-DLL3\/anti-CD47 bispecific antibody, in patients with DLL3-expressing cancers such as SCLC, LCNEC and EP-NEC (SKYBRIDGE study)","author":"Sands","year":"2025"},{"key":"B307","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-25-1483","article-title":"Circulating tumor cells predict response to the DLL3-targeting bispecific antibody tarlatamab","author":"Mishra","year":"2026"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03792-7","article-title":"A bispecific antibody\u2013drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat Med"},{"key":"B309","article-title":"NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer (Version 3.2026)","year":"2026"},{"key":"B310","doi-asserted-by":"publisher","first-page":"116747","DOI":"10.1016\/j.intimp.2026.116747","article-title":"The rise of bispecific antibodies for dual targeting, singular impact: technology and clinical advancements","volume":"181","author":"Pandey","year":"2026"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1927829\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:11:26Z","timestamp":1788955886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1927829\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":310,"alternative-id":["10.3389\/fonc.2026.1927829"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1927829","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1927829"}}